Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA ® trial
ConclusionsIn Asian patients, linagliptin demonstrated similar CV safety to glimepiride with a markedly lower rate of hypoglycemia and modestly lower weight. (Source: Diabetology International)
Source: Diabetology International - June 26, 2020 Category: Endocrinology Source Type: research
Ethics and practical mitigations for ongoing clinical trials during the COVID-19 pandemic
(Source: Diabetology International)
Source: Diabetology International - June 18, 2020 Category: Endocrinology Source Type: research
The work style and living condition survey of diabetologists and the expectations for the Japan Diabetes Society: results of questionnaires about the current state and the future prospect of their carrier in 2017
AbstractThe Japan Diabetes Society ’s Committee to Promote Female Diabetologists conducted a questionnaire survey from May to June 2017 to investigate the work style and living situation of diabetologists. The survey targeted 5298 Board Certified Diabetologists (diabetologists), with answers obtained from 1566 diabetologists (male,n = 1003: females,n = 563). Ninety-four percent of the males and 72% of the females worked full time. Twenty-one percent of the male subjects and 7% of the female subjects were heads of clinical departments, and 23% of the male subjects and 13% of the female subjects were diabetes train...
Source: Diabetology International - June 14, 2020 Category: Endocrinology Source Type: research
Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report
AbstractWe herein report the clinical course of a 56-year-old Japanese patient with slowly progressive type 1 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease, and severe insulin resistance. The patient ’s intravenous glucose tolerance test indicated marked reductions in insulin sensitivity and endogenous insulin secretion. Accordingly, administration of ipragliflozinl-proline, a sodium-glucose cotransporter 2 inhibitor, promoted improvements in insulin sensitivity and blood glucose levels, as well as a decrease in visceral fat, improvement in dyslipidemia, and decrease in hepatic lipid content, s...
Source: Diabetology International - June 11, 2020 Category: Endocrinology Source Type: research
Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches
AbstractDiabetic kidney disease (DKD), a microvascular complication of diabetes, has been the leading cause of end-stage kidney disease (ESKD). Accordingly, patients with type 2 diabetes mellitus (T2DM) develop renal damage due to multiple metabolic and cardiorenal disease-related risk factors, including hyperglycemia, hypertension, dyslipidemia, hyperuricemia, and overnutrition/obesity. Despite multifactorial management including the administration of renin –angiotensin system inhibitors, patients often do not experience sufficient suppression of DKD progression and, thus, remain at risk for ESKD. Recent studies on card...
Source: Diabetology International - June 10, 2020 Category: Endocrinology Source Type: research
Promising roles of sodium –glucose cotransporter 2 inhibitors in heart failure prevention and treatment
AbstractIn recent years, successive reports have been made on large-scale cardiovascular outcome trials using novel hypoglycemic drugs. Their results have shown that sodium –glucose cotransporter 2 (SGLT2) inhibitors are hypoglycemic drugs that could potentially greatly improve the heart failure-related outcomes in type 2 diabetes patients with a high cardiovascular risk. Further analyses have subsequently been performed from various perspectives, and SGLT2 inhibitor s with their class effect have been indicated to be potentially useful for heart failure in type 2 diabetes patients with extensive clinical background. As ...
Source: Diabetology International - June 10, 2020 Category: Endocrinology Source Type: research
Aldose reductase (AC)n gene polymorphism in Iranian patients with type 2 diabetic microangiopathy; a case –control study
ConclusionOur results showed that ALR (AC)n gene polymorphism in Iranian patients with type 2 diabetes independently, predispose retinal, renal and neural microvascular to diabetic complications. (Source: Diabetology International)
Source: Diabetology International - June 9, 2020 Category: Endocrinology Source Type: research
Current understanding of the effect of sodium –glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus
(Source: Diabetology International)
Source: Diabetology International - June 7, 2020 Category: Endocrinology Source Type: research
Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor
AbstractCeritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor with clinical activity in crizotinib-resistant ALK-positive non-small cell lung cancer and in treatment-na ïve ALK-positive disease. Hyperglycemia is a known adverse event, but the mechanism by which ceritinib causes hyperglycemia is unknown, and whether ceritinib causes hyperglycemic emergencies is unclear. Here, we report the case of a patient with a hyperglycemic hyperosmolar state (HHS) recurrence a fter the re-administration of dose-reduced ceritinib. A 78-year-old man with type 2 diabetes diagnosed as having advanced lung adenocarcin...
Source: Diabetology International - June 1, 2020 Category: Endocrinology Source Type: research
Characteristics of patients who developed glucose intolerance in the early period after partial pancreatectomy
ConclusionAfter undergoing a partial pancreatectomy, approximately 30% of the patients developed glucose intolerance during the hospitalized period. Our findings indicate that pre-operative HbA1c and post-operative HOMA-IR values can be associated with developing glucose intolerance just after partial pancreatectomy. (Source: Diabetology International)
Source: Diabetology International - May 27, 2020 Category: Endocrinology Source Type: research
Glycemic control of people with diabetes over months after the 2018 North Osaka Earthquake
ConclusionGlycemic control was significantly deteriorated over months after the 2018 North Osaka Earthquake despite limited damage of lifelines and transportation networks. The deterioration was more prevalent in areas with a high seismic intensity. (Source: Diabetology International)
Source: Diabetology International - May 25, 2020 Category: Endocrinology Source Type: research
Correction to: Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes
In the original publication, the unit of C-peptide immunoreactivity. (Source: Diabetology International)
Source: Diabetology International - April 22, 2020 Category: Endocrinology Source Type: research
Effect of tasteless calorie-free gum chewing before meal on postprandial plasma glucose, insulin, glucagon, and gastrointestinal hormones in Japanese men without diagnosed glucose metabolism disorder: a pilot randomized crossover trial
In conclusion, the current pilot study demonstrated that tasteless calorie-free gum chewing before rice eating had a significant but limited impact on the increase of postprandi al active GLP-1 levels in male individuals without diagnosed glucose metabolism disorder. (Source: Diabetology International)
Source: Diabetology International - April 10, 2020 Category: Endocrinology Source Type: research
Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes
We describe a case, in which an extremely low dose of repaglinide caused severe hypoglycemia and novel drug interactions are suggested. A 71-year-old man with type 2 diabetes was taken to the hospital due to consciousness disorder caused by severe hypoglycemia. He was taking repaglinide 0.25 mg once in the morning with nilotinib 400 mg/day and febuxostat 20 mg/day. Endogenous insulin secretion was not suppressed even in hypoglycemia. Detection of plasma repaglinide 10 h after administration in this case indicates delayed elimination of the agent, which might be derived from reduced hepatocyte uptake due to inhibitory ...
Source: Diabetology International - April 7, 2020 Category: Endocrinology Source Type: research
Effect of postprandial moderate-intensity walking for 15-min on glucose homeostasis in type 2 diabetes mellitus patients
ConclusionThese results suggest that postprandial moderate-intensity walking, easily performable in daily life activities, was effective for improving glucose homeostasis. Further study should be performed to clarify the relationship between postprandial walk and drug therapy (insulin and OHA), including insulin secretory ability. (Source: Diabetology International)
Source: Diabetology International - April 2, 2020 Category: Endocrinology Source Type: research
